source
- Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo B therapySpruce Biosciences reported progress toward filing its enzyme replacement therapy, tralesinidase alfa (TA-ERT), for Sanfilippo syndrome type B, an ultra-rare lysosomal disorder. The company said t…
- Pharma marketers urged to adopt share-of-answer strategy as AI use surges among physiciansPharma marketers are planning for 2027 as artificial intelligence reshapes how clinicians seek clinical answers. The rise of AI tools means that traditional metrics like share of voice and broad om…